{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:03:22Z","timestamp":1788498202107,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008714","name":"Motor Neurone Disease Research Institute of Australia","doi-asserted-by":"publisher","award":["Bill Gole Postdoctoral Fellowship"],"award-info":[{"award-number":["Bill Gole Postdoctoral Fellowship"]}],"id":[{"id":"10.13039\/100008714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001777","name":"University of Wollongong","doi-asserted-by":"publisher","award":["Yerbury Family Scholarship"],"award-info":[{"award-number":["Yerbury Family Scholarship"]}],"id":[{"id":"10.13039\/501100001777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1095215"],"award-info":[{"award-number":["1095215"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ainsworth Medical Research Innovation Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The synthetic copper-containing compound, CuATSM, has emerged as one of the most promising drug candidates developed for the treatment of amyotrophic lateral sclerosis (ALS). Multiple studies have reported CuATSM treatment provides therapeutic efficacy in various mouse models of ALS without any observable adverse effects. Moreover, recent results from an open label clinical study suggested that daily oral dosing with CuATSM slows disease progression in patients with both sporadic and familial ALS, providing encouraging support for CuATSM in the treatment of ALS. Here, we assessed CuATSM in high copy <jats:italic>SOD1<\/jats:italic><jats:sup><jats:italic>G93A<\/jats:italic><\/jats:sup> mice on the congenic C57BL\/6 background, treating at 100\u00a0mg\/kg\/day by gavage, starting at 70\u00a0days of age. This dose in this specific model has not been assessed previously. Unexpectedly, we report a subset of mice initially administered CuATSM exhibited signs of clinical toxicity, that necessitated euthanasia in extremis after 3\u201351\u00a0days of treatment. Following a 1-week washout period, the remaining mice resumed treatment at the reduced dose of 60\u00a0mg\/kg\/day. At this revised dose, treatment with CuATSM slowed disease progression and increased survival relative to vehicle-treated littermates. This work provides the first evidence that CuATSM produces positive disease-modifying outcomes in high copy <jats:italic>SOD1<\/jats:italic><jats:sup><jats:italic>G93A<\/jats:italic><\/jats:sup> mice on a congenic C57BL\/6 background. Furthermore, results from the 100\u00a0mg\/kg\/day phase of the study support dose escalation determination of tolerability as a prudent step when assessing treatments in previously unassessed models or genetic backgrounds.<\/jats:p>","DOI":"10.1038\/s41598-021-98317-w","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T10:25:07Z","timestamp":1632911107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL\/6 background"],"prefix":"10.1038","volume":"11","author":[{"given":"Jeremy S.","family":"Lum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Farrawell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"McAlary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen G.","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Vine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Karl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kreilaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan E.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nikseresht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Yerbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"98317_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942\u2013955 (2011).","journal-title":"Lancet"},{"key":"98317_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon, G., Lacomblez, L. & Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N. Engl. J. Med. 330, 585\u2013591 (1994).","journal-title":"N. Engl. J. Med."},{"key":"98317_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P. & Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet 347, 1425\u20131431 (1996).","journal-title":"Lancet"},{"key":"98317_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2017.1361447","volume":"18","author":"RG Miller","year":"2017","unstructured":"Miller, R. G. & Appel, S. H. Introduction to supplement: The current status of treatment for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 1\u20134 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"98317_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/21678421.2017.1369125","volume":"18","author":"A Al-Chalabi","year":"2017","unstructured":"Al-Chalabi, A. et al. July 2017 ENCALS statement on edaravone. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 471\u2013474 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"98317_CR6","doi-asserted-by":"publisher","DOI":"10.2196\/mhealth.2706","volume":"1","author":"O Abel","year":"2013","unstructured":"Abel, O. et al. Development of a smartphone app for a genetics website: The Amyotrophic Lateral Sclerosis Online Genetics Database (ALSoD). JMIR mHealth uHealth 1, e18 (2013).","journal-title":"JMIR mHealth uHealth"},{"key":"98317_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jns.2019.02.030","volume":"399","author":"S Mathis","year":"2019","unstructured":"Mathis, S., Goizet, C., Soulages, A., Vallat, J.-M. & Masson, G. L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 399, 217\u2013226 (2019).","journal-title":"J. Neurol. Sci."},{"key":"98317_CR8","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.1073\/pnas.91.17.8292","volume":"91","author":"DR Borchelt","year":"1994","unstructured":"Borchelt, D. R. et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. U.S.A. 91, 8292\u20138296 (1994).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"98317_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng0596-43","volume":"13","author":"AG Reaume","year":"1996","unstructured":"Reaume, A. G. et al. Motor neurons in Cu\/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13, 43\u201347 (1996).","journal-title":"Nat. Genet."},{"key":"98317_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0006-8993(95)00063-V","volume":"676","author":"MC Dal Canto","year":"1995","unstructured":"Dal Canto, M. C. & Gurney, M. E. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676, 25\u201340 (1995).","journal-title":"Brain Res."},{"key":"98317_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1006\/nbdi.2000.0299","volume":"7","author":"D Jaarsma","year":"2000","unstructured":"Jaarsma, D. et al. Human Cu\/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 7, 623\u2013643 (2000).","journal-title":"Neurobiol. Dis."},{"key":"98317_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pneurobio.2008.01.001","volume":"85","author":"BJ Turner","year":"2008","unstructured":"Turner, B. J. & Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85, 94\u2013134 (2008).","journal-title":"Prog. Neurobiol."},{"key":"98317_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"AE Renton","year":"2014","unstructured":"Renton, A. E., Chi\u00f2, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17\u201323 (2014).","journal-title":"Nat. Neurosci."},{"key":"98317_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4103\/1673-5374.255962","volume":"14","author":"L McAlary","year":"2019","unstructured":"McAlary, L. & Yerbury, J. J. Strategies to promote the maturation of ALS-associated SOD1 mutants: Small molecules return to the fold. Neural Regen. Res. 14, 1511\u20131512 (2019).","journal-title":"Neural Regen. Res."},{"key":"98317_CR15","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1021\/bi00147a003","volume":"31","author":"G Mei","year":"1992","unstructured":"Mei, G. et al. Denaturation of human copper-zinc superoxide dismutase by guanidine hydrochloride: A dynamic fluorescence study. Biochemistry 31, 7224\u20137230 (1992).","journal-title":"Biochemistry"},{"key":"98317_CR16","doi-asserted-by":"publisher","first-page":"15932","DOI":"10.1074\/jbc.M112088200","volume":"277","author":"JA Rodriguez","year":"2002","unstructured":"Rodriguez, J. A. et al. Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper\/zinc superoxide dismutase. J. Biol. Chem. 277, 15932\u201315937 (2002).","journal-title":"J. Biol. Chem."},{"key":"98317_CR17","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1523\/JNEUROSCI.4196-13.2014","volume":"34","author":"BR Roberts","year":"2014","unstructured":"Roberts, B. R. et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 34, 8021\u20138031 (2014).","journal-title":"J. Neurosci."},{"key":"98317_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2016.01.020","volume":"89","author":"JR Williams","year":"2016","unstructured":"Williams, J. R. et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol. Dis. 89, 1\u20139 (2016).","journal-title":"Neurobiol. Dis."},{"key":"98317_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1039\/C6MT00099A","volume":"8","author":"JB Hilton","year":"2016","unstructured":"Hilton, J. B., White, A. R. & Crouch, P. J. Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS. Metallomics 8, 1002\u20131011 (2016).","journal-title":"Metallomics"},{"key":"98317_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep42292","volume":"7","author":"JB Hilton","year":"2017","unstructured":"Hilton, J. B. et al. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. 7, 42292 (2017).","journal-title":"Sci. Rep."},{"key":"98317_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035241","volume":"7","author":"JY Kwan","year":"2012","unstructured":"Kwan, J. Y. et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: Correlating 7 Tesla MRI and pathology. PLoS\u00a0One 7, e35241 (2012).","journal-title":"PLoS\u00a0One"},{"key":"98317_CR22","doi-asserted-by":"crossref","unstructured":"Hilton, J. B. Disrupted copper availability in sporadic ALS: Implications for CuII (atsm) as a treatment option. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.17.047704v1 (2020).","DOI":"10.1101\/2020.04.17.047704"},{"key":"98317_CR23","doi-asserted-by":"publisher","first-page":"44035","DOI":"10.1074\/jbc.M111.274407","volume":"286","author":"CPW Soon","year":"2011","unstructured":"Soon, C. P. W. et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 286, 44035\u201344044 (2011).","journal-title":"J. Biol. Chem."},{"key":"98317_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/21678421.2013.824000","volume":"14","author":"EJ McAllum","year":"2013","unstructured":"McAllum, E. J. et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 586\u2013590 (2013).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"98317_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1084\/jem.20112285","volume":"209","author":"LW Hung","year":"2012","unstructured":"Hung, L. W. et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson\u2019s disease. J. Exp. Med. 209, 837\u2013854 (2012).","journal-title":"J. Exp. Med."},{"key":"98317_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s13311-016-0504-9","volume":"14","author":"MT Huuskonen","year":"2017","unstructured":"Huuskonen, M. T. et al. The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu. Neurotherapeutics 14, 519\u2013532 (2017).","journal-title":"Neurotherapeutics"},{"key":"98317_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00668","volume":"12","author":"XY Choo","year":"2018","unstructured":"Choo, X. Y. et al. CuII(atsm) Attenuates Neuroinflammation. Front. Neurosci. 12, 668 (2018).","journal-title":"Front. Neurosci."},{"key":"98317_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11302-020-09692-4","volume":"16","author":"D Ly","year":"2020","unstructured":"Ly, D. et al. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice. Purinergic Signal 16, 109\u2013122 (2020).","journal-title":"Purinergic Signal"},{"key":"98317_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ibror.2017.03.001","volume":"2","author":"FG Vieira","year":"2017","unstructured":"Vieira, F. G. et al. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep. 2, 47\u201353 (2017).","journal-title":"IBRO Rep."},{"key":"98317_CR30","unstructured":"Rowe, D., Mathers, S. & Smith, G. Modification of ALS disease progression in a phase 1 trial of CuATSM. 29th International Symposium on ALS\/MND Glasgow (2018)."},{"key":"98317_CR31","unstructured":"Hebert, C. NTP technical report on the toxicity studies of cupric sulfate (CAS No. 7758-99-8) administered in drinking water and feed to F344\/N rats and B6C3F1 mice. Toxicity Report Series 29, 1-D3 (1993)."},{"key":"98317_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtemb.2014.06.004","volume":"29","author":"V Kumar","year":"2015","unstructured":"Kumar, V., Kalita, J., Misra, U. K. & Bora, H. K. A study of dose response and organ susceptibility of copper toxicity in a rat model. J. Trace Elem. Med. Biol. 29, 269\u2013274 (2015).","journal-title":"J. Trace Elem. Med. Biol."},{"key":"98317_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12011-013-9665-0","volume":"153","author":"A Pal","year":"2013","unstructured":"Pal, A. et al. Biochemical, histological, and memory impairment effects of chronic copper toxicity: A model for non-Wilsonian brain copper toxicosis in Wistar rat. Biol. Trace Elem. Res. 153, 257\u2013268 (2013).","journal-title":"Biol. Trace Elem. Res."},{"key":"98317_CR34","first-page":"1155","volume":"38","author":"Y Fujibayashi","year":"1997","unstructured":"Fujibayashi, Y. et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 38, 1155\u20131160 (1997).","journal-title":"J. Nucl. Med."},{"key":"98317_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.11.004","author":"J Dearling","year":"2010","unstructured":"Dearling, J. & Packard, A. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl. Med. Biol. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.11.004 (2010).","journal-title":"Nucl. Med. Biol."},{"key":"98317_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1073\/pnas.1116227108","volume":"109","author":"PS Donnelly","year":"2012","unstructured":"Donnelly, P. S. et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copperII. Proc. Natl. Acad. Sci. U.S.A. 109, 47\u201352 (2012).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"98317_CR37","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.freeradbiomed.2016.10.275","volume":"100","author":"L Padgitt-Cobb","year":"2016","unstructured":"Padgitt-Cobb, L. 234-Investigation into the oxidation of CuATSM as a mechanism for copper release. Free Radic. Biol. Med. 100, S107 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"98317_CR38","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1021\/acs.inorgchem.8b00853","volume":"57","author":"JJ Sirois","year":"2018","unstructured":"Sirois, J. J. et al. Oxidative release of copper from pharmacologic copper bis(thiosemicarbazonato) compounds. Inorg. Chem. 57, 8923\u20138932 (2018).","journal-title":"Inorg. Chem."},{"key":"98317_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","volume":"363","author":"T Sousa","year":"2008","unstructured":"Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1\u201325 (2008).","journal-title":"Int. J. Pharm."},{"key":"98317_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","volume":"570","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462\u2013467 (2019).","journal-title":"Nature"},{"key":"98317_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/PL00020155","volume":"27","author":"C Farr","year":"1989","unstructured":"Farr, C. & Hunt, D. M. Genetic differences in zinc and copper induction of liver metallothionein in inbred strains of the mouse. Biochem. Genet. 27, 199\u2013217 (1989).","journal-title":"Biochem. Genet."},{"key":"98317_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2353\/ajpath.2006.050312","volume":"168","author":"D Huster","year":"2006","unstructured":"Huster, D. et al. Consequences of copper accumulation in the livers of the Atp7b\u2212\/\u2212 (Wilson disease gene) knockout mice. Am. J. Pathol. 168, 423\u2013434 (2006).","journal-title":"Am. J. Pathol."},{"key":"98317_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2005.02.006","volume":"236","author":"TD Heiman-Patterson","year":"2005","unstructured":"Heiman-Patterson, T. D. et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 236, 1\u20137 (2005).","journal-title":"J. Neurol. Sci."},{"key":"98317_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/17482968.2010.550626","volume":"12","author":"TD Heiman-Patterson","year":"2011","unstructured":"Heiman-Patterson, T. D. et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers. Amyotroph. Lateral Scler. 12, 79\u201386 (2011).","journal-title":"Amyotroph. Lateral Scler."},{"key":"98317_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3109\/17482968.2012.662688","volume":"13","author":"R Mancuso","year":"2012","unstructured":"Mancuso, R. et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 13, 302\u2013310 (2012).","journal-title":"Amyotroph. Lateral Scler."},{"key":"98317_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JND-140068","volume":"2","author":"SR Pfohl","year":"2015","unstructured":"Pfohl, S. R., Halicek, M. T. & Mitchell, C. S. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: A meta-analysis. J. Neuromusc. Dis. 2, 137\u2013150 (2015).","journal-title":"J. Neuromusc. Dis."},{"key":"98317_CR47","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.neuroscience.2004.09.069","volume":"130","author":"PS Sharp","year":"2005","unstructured":"Sharp, P. S., Dick, J. R. T. & Greensmith, L. The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neuroscience 130, 897\u2013910 (2005).","journal-title":"Neuroscience"},{"key":"98317_CR48","doi-asserted-by":"publisher","first-page":"11159","DOI":"10.1073\/pnas.0402026101","volume":"101","author":"L Dupuis","year":"2004","unstructured":"Dupuis, L., Oudart, H., Ren\u00e9, F., Gonzalez de Aguilar, J.-L. & Loeffler, J.-P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. U.S.A. 101, 11159\u201311164 (2004).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"98317_CR49","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acschemneuro.8b00527","volume":"10","author":"NE Farrawell","year":"2019","unstructured":"Farrawell, N. E., Yerbury, M. R., Plotkin, S. S., McAlary, L. & Yerbury, J. J. CuATSM protects against the in vitro cytotoxicity of wild-type-like copper-zinc superoxide dismutase mutants but not mutants that disrupt metal binding. ACS Chem. Neurosci. 10, 1555\u20131564 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"98317_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104495","volume":"130","author":"MTH Kuo","year":"2019","unstructured":"Kuo, M. T. H., Beckman, J. S. & Shaw, C. A. Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model. Neurobiol. Dis. 130, 104495 (2019).","journal-title":"Neurobiol. Dis."},{"key":"98317_CR51","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/life10110271","volume":"10","author":"S Nikseresht","year":"2020","unstructured":"Nikseresht, S., Hilton, J. B. W., Kysenius, K., Liddell, J. R. & Crouch, P. J. Copper-ATSM as a treatment for ALS: Support from mutant SOD1 models and beyond. Life 10, 271 (2020).","journal-title":"Life"},{"key":"98317_CR52","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bph.14881","volume":"177","author":"A Southon","year":"2020","unstructured":"Southon, A. et al. CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br. J. Pharmacol. 177, 656\u2013667 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"98317_CR53","doi-asserted-by":"publisher","unstructured":"Blower, P. J. et al. Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans. 4416\u20134425 (2003). https:\/\/doi.org\/10.1039\/B307499D.","DOI":"10.1039\/B307499D"},{"key":"98317_CR54","doi-asserted-by":"publisher","DOI":"10.3791\/53257","author":"T Hatzipetros","year":"2015","unstructured":"Hatzipetros, T. et al. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. J. Vis. Exp. https:\/\/doi.org\/10.3791\/53257 (2015).","journal-title":"J. Vis. Exp."},{"key":"98317_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1078\/0940-2993-00301","volume":"55","author":"T Karl","year":"2003","unstructured":"Karl, T., Pabst, R. & von H\u00f6rsten, S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp. Toxicol. Pathol. 55, 69\u201383 (2003).","journal-title":"Exp. Toxicol. Pathol."},{"key":"98317_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"98317_CR57","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/0003-2697(71)90370-8","volume":"44","author":"C Beauchamp","year":"1971","unstructured":"Beauchamp, C. & Fridovich, I. Superoxide dismutase: Improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 44, 276\u2013287 (1971).","journal-title":"Anal. Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98317-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98317-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98317-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T21:10:51Z","timestamp":1675717851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98317-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98317"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98317-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Collaborative Medicinal Development LLC has licensed intellectual property related to this subject from the University of Melbourne where the inventors include PSD. PJC is an unpaid consultant for Collaborative Medicinal Development LLC. JSL, MLB, NEF, LM, DL, CGC, JS, KLV, TK, FK, LEM, SN, JJY declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19392"}}